David Amsellem
Stock Analyst at Piper Sandler
(4.83)
# 78
Out of 5,090 analysts
163
Total ratings
67.19%
Success rate
24.12%
Average return
Main Sectors:
Stocks Rated by David Amsellem
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ESPR Esperion Therapeutics | Initiates: Overweight | $9 | $3.73 | +141.29% | 1 | Nov 25, 2025 | |
| BIIB Biogen | Reiterates: Neutral | $118 → $157 | $181.30 | -13.40% | 3 | Nov 21, 2025 | |
| AMGN Amgen | Maintains: Overweight | $342 → $381 | $329.89 | +15.49% | 6 | Nov 14, 2025 | |
| AQST Aquestive Therapeutics | Maintains: Overweight | $5 → $8 | $6.38 | +25.39% | 2 | Nov 7, 2025 | |
| XERS Xeris Biopharma Holdings | Maintains: Neutral | $6 → $8 | $6.51 | +22.89% | 6 | Nov 7, 2025 | |
| ABBV AbbVie | Reiterates: Overweight | $284 → $289 | $226.08 | +27.83% | 2 | Nov 5, 2025 | |
| INDV Indivior | Reiterates: Overweight | $27 → $41 | $35.12 | +16.74% | 6 | Oct 31, 2025 | |
| AMRX Amneal Pharmaceuticals | Reiterates: Overweight | $11 → $13 | $12.18 | +6.73% | 5 | Oct 31, 2025 | |
| NBIX Neurocrine Biosciences | Maintains: Overweight | $175 → $179 | $155.51 | +15.11% | 12 | Oct 29, 2025 | |
| ALKS Alkermes | Reiterates: Overweight | $38 → $45 | $29.52 | +52.44% | 8 | Oct 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $40 → $65 | $45.68 | +42.29% | 17 | Oct 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $30 → $25 | $26.77 | -6.61% | 9 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $131 → $121 | $86.11 | +40.53% | 8 | Aug 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $18 | $7.14 | +152.10% | 6 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $36 → $37 | $47.91 | -22.77% | 8 | May 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Overweight | $176 → $147 | $169.70 | -13.38% | 14 | May 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $65 | $52.15 | +24.64% | 1 | Apr 22, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Neutral | $14 → $10 | $10.93 | -8.51% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $23 → $30 | $28.46 | +5.41% | 10 | Jan 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $24 → $13 | $21.34 | -39.08% | 5 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $68 | $81.77 | -16.84% | 1 | Oct 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | $9 → $3 | $6.93 | -56.71% | 7 | Aug 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $42 | $23.99 | +75.07% | 10 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $20 → $21 | $3.48 | +503.45% | 3 | Feb 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $90 → $113 | $149.22 | -24.27% | 3 | Jan 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $72 → $42 | $39.83 | +5.45% | 3 | Oct 16, 2023 |
Esperion Therapeutics
Nov 25, 2025
Initiates: Overweight
Price Target: $9
Current: $3.73
Upside: +141.29%
Biogen
Nov 21, 2025
Reiterates: Neutral
Price Target: $118 → $157
Current: $181.30
Upside: -13.40%
Amgen
Nov 14, 2025
Maintains: Overweight
Price Target: $342 → $381
Current: $329.89
Upside: +15.49%
Aquestive Therapeutics
Nov 7, 2025
Maintains: Overweight
Price Target: $5 → $8
Current: $6.38
Upside: +25.39%
Xeris Biopharma Holdings
Nov 7, 2025
Maintains: Neutral
Price Target: $6 → $8
Current: $6.51
Upside: +22.89%
AbbVie
Nov 5, 2025
Reiterates: Overweight
Price Target: $284 → $289
Current: $226.08
Upside: +27.83%
Indivior
Oct 31, 2025
Reiterates: Overweight
Price Target: $27 → $41
Current: $35.12
Upside: +16.74%
Amneal Pharmaceuticals
Oct 31, 2025
Reiterates: Overweight
Price Target: $11 → $13
Current: $12.18
Upside: +6.73%
Neurocrine Biosciences
Oct 29, 2025
Maintains: Overweight
Price Target: $175 → $179
Current: $155.51
Upside: +15.11%
Alkermes
Oct 23, 2025
Reiterates: Overweight
Price Target: $38 → $45
Current: $29.52
Upside: +52.44%
Oct 9, 2025
Upgrades: Overweight
Price Target: $40 → $65
Current: $45.68
Upside: +42.29%
Aug 8, 2025
Maintains: Neutral
Price Target: $30 → $25
Current: $26.77
Upside: -6.61%
Aug 1, 2025
Maintains: Overweight
Price Target: $131 → $121
Current: $86.11
Upside: +40.53%
May 15, 2025
Maintains: Overweight
Price Target: $24 → $18
Current: $7.14
Upside: +152.10%
May 9, 2025
Reiterates: Neutral
Price Target: $36 → $37
Current: $47.91
Upside: -22.77%
May 7, 2025
Reiterates: Overweight
Price Target: $176 → $147
Current: $169.70
Upside: -13.38%
Apr 22, 2025
Initiates: Overweight
Price Target: $65
Current: $52.15
Upside: +24.64%
Mar 5, 2025
Reiterates: Neutral
Price Target: $14 → $10
Current: $10.93
Upside: -8.51%
Jan 17, 2025
Maintains: Overweight
Price Target: $23 → $30
Current: $28.46
Upside: +5.41%
Jan 10, 2025
Maintains: Overweight
Price Target: $24 → $13
Current: $21.34
Upside: -39.08%
Oct 11, 2024
Initiates: Overweight
Price Target: $68
Current: $81.77
Upside: -16.84%
Aug 2, 2024
Downgrades: Underweight
Price Target: $9 → $3
Current: $6.93
Upside: -56.71%
Jul 3, 2024
Maintains: Overweight
Price Target: $42
Current: $23.99
Upside: +75.07%
Feb 16, 2024
Maintains: Overweight
Price Target: $20 → $21
Current: $3.48
Upside: +503.45%
Jan 16, 2024
Maintains: Overweight
Price Target: $90 → $113
Current: $149.22
Upside: -24.27%
Oct 16, 2023
Maintains: Overweight
Price Target: $72 → $42
Current: $39.83
Upside: +5.45%